Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), anticipates a significant increase in profits for the fiscal year ending December 31, 2025, projecting earnings between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to an estimated profit of about $2.7 million for the fiscal year ending December 31, 2024 [1]. Financial Projections - The adjusted total profit is expected to range from $91 million (approximately HKD 708 million) to $98 million (approximately HKD 763 million) [1]. - The profit increase is primarily attributed to the continuous growth of the company's recurring revenue [1]. Revenue Drivers - Revenue growth is supported by research collaborations with AstraZeneca and Bristol-Myers Squibb [1]. - The accelerated expansion of the global partnership network has also contributed to revenue growth, including licensing collaborations with Otsuka Pharmaceutical and Windward Bio [1]. - Rapid growth in the business of Nona Bio, including revenue from technology licensing and platform-based services, as well as milestone payments from research and technology licensing collaborations with Pfizer, has further enhanced revenue [1].

Core Viewpoint - The company expects a significant increase in profit for the fiscal year ending December 31, 2025, projecting a profit between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to a profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Group 1: Profit Projections - Expected profit for the fiscal year ending December 31, 2025, is projected to be between $88 million and $95 million [1] - For the fiscal year ending December 31, 2024, the expected profit is approximately $2.7 million [1] - Adjusted total profit is anticipated to be between $91 million (approximately HKD 708 million) and $98 million (approximately HKD 763 million) [1] Group 2: Revenue Growth Drivers - The increase in expected profit is primarily attributed to the continuous growth of the company's recurring revenue [1] - Collaborations with AstraZeneca and Bristol-Myers Squibb are contributing to the recurring revenue through platform-based research partnerships [1] - The global partner network is expanding, leading to revenue from licensing and collaborations, such as partnerships with Otsuka Pharmaceutical and Windward Bio [1] Group 3: Business Expansion - The rapid growth of Nona Bio's business is contributing to revenue through technology licensing and platform-based services [1] - Revenue from milestone payments from existing collaborations, including research and technology licensing with Pfizer, is also a significant factor [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142.HK), anticipates a significant increase in profit for the fiscal year ending December 31, 2025, projecting earnings between approximately $88 million (around HKD 685 million) and $95 million (around HKD 739 million), compared to an estimated profit of about $2.7 million for the fiscal year ending December 31, 2024 [1] Group 1 - The expected increase in profit is primarily attributed to the continuous growth of the company's recurring revenue [1] - The company has expanded its global partnership network, which has accelerated due to revenue generated from licensing and collaboration on innovative products [1] - Notable collaborations include partnerships with AstraZeneca, Bristol-Myers Squibb, Otsuka Pharmaceutical, and Windward Bio, contributing to the recurring revenue stream [1] Group 2 - The rapid growth of the business segment related to Nona Bio is highlighted, including revenue from technology licensing and platform-based services [1] - Milestone payments from existing collaborations, such as research and technology licensing agreements with Pfizer, are also contributing to revenue growth [1]

Group 1 - The U.S. stock market experienced a collective decline, with the Dow Jones down 0.34%, Nasdaq down 1.43%, and S&P 500 down 0.83%, indicating a bearish sentiment in the tech sector as major companies like Broadcom, Microsoft, Nvidia, and Meta saw significant drops [3] - International oil prices rose, with WTI crude oil increasing by 3.12% to $64.08 per barrel and Brent crude oil up by 2.88% to $68.21 per barrel, reflecting a positive trend in the energy sector [4] - European stock indices closed slightly lower, with Germany's DAX down 0.07%, France's CAC40 down 0.02%, and the UK's FTSE 100 down 0.26%, indicating a cautious market environment in Europe [5] Group 2 - The Central Committee of the Communist Party of China released a document focusing on agricultural modernization and rural revitalization, emphasizing the need for technological innovation in agriculture and the development of key agricultural technologies [6] - The Ministry of Industry and Information Technology of China highlighted the importance of advancing in fields such as 6G, quantum technology, and bio-manufacturing, aiming for breakthroughs in these future industries [9] - The People's Bank of China announced an operation to conduct 800 billion yuan of reverse repos to maintain liquidity in the banking system, indicating a proactive monetary policy stance [10] Group 3 - The recent news regarding the "couple's online purchase of contaminated vegetables" led to legal actions against the individuals involved for extortion, showcasing the legal implications of consumer safety issues [11] - The incident at Lingyin Temple, where 380,000 reservations were made but many did not show up, prompted a review of the reservation system to improve attendance and manage visitor expectations [12] - Reports of potential increases in VAT rates for the gaming and financial sectors were dismissed by experts, reinforcing the stability of current tax policies in these industries [13] Group 4 - The announcement of a large-scale robot gala by Zhiyuan Robotics, set to be broadcasted globally, signifies a growing interest in integrating robotics with entertainment, potentially influencing the tech and entertainment sectors [21] - The response from Chaozhou Jewelry regarding quality concerns over their products, backed by authoritative testing, aims to maintain brand reputation and consumer trust [23] - Tencent's revival of the classic QQ Farm game is expected to enhance user engagement and interaction, reflecting a trend in leveraging nostalgia in gaming [24]

标普500指数与纳斯达克指数周二料稳健高开，在前一交易日大宗商品暴跌后企稳，投资者正为本周密 集来袭的企业财报季做好准备。 帕兰提尔科技盘前股价大涨11.2%，该公司靓丽财报凸显其军用级人工智能工具需求旺盛，美国国防开 支助力季度销售额增长。 泰瑞达股价飙升22%，这家芯片测试设备制造商发布强劲一季度业绩指引，受益于另一波人工智能相关 投资热潮——大型科技企业正斥资数十亿美元推进数据中心扩建。 全泉全球投资高级投资组合经理约翰・坎贝尔表示："帕兰提尔的优异财报对人工智能板块行情形成支 撑。" 谷歌母公司Alphabet在前一交易日创历史新高后，盘前再涨1.3%；亚马逊上涨0.8%。这两家"七大科技 巨头"均将于本周晚些时候发布财报，将为投资者提供人工智能商业化竞赛的最新参考。 超微半导体及服务器制造商美超微电脑均将于当日收盘后发布财报，盘前股价均上涨约2%。 坎贝尔补充道："我们注意到，不少短线资金会在财报发布前提前布局相关个股，押注财报发布后股价 上涨，目前这种情况确实存在。" 头部科技企业近期发布的财报凸显，投资者愈发关注巨额资本支出计划的回报情况。人工智能相关基础 设施投入大幅攀升，企业面临压力，需将投 ...

被分析师誉为"一流人工智能助力者"的帕兰泰尔将于2月2日收盘后公布2025年第四季度业绩，交易员普遍预测财报发布后股价将出现显著波动。根据当前 期权价格推算，到本周末，其股价可能至少上涨9%，也存在跌至133美元附近的可能。 美国软件与服务公司Palantir（帕兰泰尔）将于当地时间2月2日公布财报，由此拉开本周美股Q4财报季序幕。 据悉，本周预计有100余家美国公司发布财报，除了帕兰泰尔以外，迪士尼、谷歌母公司Alphabet、AMD以及亚马逊等皆受到投资者重点关注。 分析师对帕兰泰尔股票的看法存在非常明显的分歧。美国银行证券的Mariana Perez Mora重申对该股持买入评级，但未披露目标价格；RBC资本的Rishi Jaluria则对该股持卖出评级，目标价为50美元。在咨询平台Visible Alpha追踪的9位分析师中，对该股的评级为四个"买入"和五个"持有"。不过，这些评级 的平均目标价约为189美元，意味着分析师认为该股仍有约30%的上涨空间，有望突破去年11月创下的历史高点。 除帕兰泰尔外，同日还有迪士尼、泰森食品等发布财报，AMD、辉瑞等将于2月3日跟进，Alphabet、礼来公司、芝商 ...

智通财经APP获悉，中金发布研报称，维持石药集团(01093)"跑赢行业"评级，考虑对外授权持续兑现上 调目标价9.1%到12港元。该行维持公司25/26年盈利预测47.60亿元/53.53亿元，引入2027年56.95亿元预 期。石药集团公告与阿斯利康签订研发合作与授权协议。 中金主要观点如下： 2025年11月，辉瑞经过与诺和诺德激烈竞价最终以100亿美元对价实现对减肥药研发企业Metsera的收 购，Metsera基于其专有NuSH平台实现了MET-097(GLP-1，临床II期)的超长半衰期，使其具备每月注射 一次的药代动力学基础。而公司SYH2082是一款正推进至临床I期的每月一次注射长效GLP1R/GIP激动 剂，该行期待有更多优异疗效和安全性数据读出。 中国创新药授权出海再获里程碑式突破 对外授权持续兑现，有望形成常态化收入 根据公告，石药集团及附属公司授权阿斯利康在全球范围内(除中国内地/港澳台)独家开发、生产和商业 化8个创新长效多肽药物项目(包括SYH2082及3个临床前阶段分子，并就另4个新增项目进行合作)，阿 斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/ ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

中国创新药出海BD再获里程碑式突破！ 1月30日，石药集团宣布已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以利用集团 专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。若后续所有研发及销售里 程碑均达成，石药集团方面有权获得总计高达185亿美元的款项。 据不完全统计，本次交易刷新了中国药企BD交易总金额最高纪录，超过了此前启德医药与 Biohaven&AimedBio达成的一笔130亿美元交易。其12亿美元的预付款，仅次于此前三生制药与辉瑞就 PD-1/VEGF达成的数额。 不过，二级市场反应不佳，石药集团股价高开低走，盘中一度狂泻近13%，收跌10.2%。什么原因？分 析人士指出，或系多方面因素叠加影响。 从石药集团股价近日表现来看，市场可能提前定价。在此次协议公告前，石药集团已连续多日强势上 涨，尤其在1月28日，股价单日大涨6.14%创年内新高。公告发布后，部分资金可能选择获利了结，形 成"利好兑现"式抛压。 从业绩贡献来看，尽管协议总金额高达185亿美元，但预付款为12亿美元，其余173亿美元为研发与销售 里程碑付款，需在未来数年、多个临床阶段成功推进后方可兑现，短期现 ...

国家统计局：2026年1月份中国制造业采购经理指数为49.3% 比上月下降0.8个百分点 国家统计局、中国物流与采购联合会31日发布2026年1月份中国采购经理指数。数据显示，1 月我国制造业市场需求有所收紧，但企业生产保持扩张态势，产业结构继续优化；服务业运行 态势相对稳定，企业预期持续向好。2026年1月份中国制造业采购经理指数为49.3%，比上月 下降0.8个百分点。1月份装备制造业采购经理指数为50.1%，高技术制造业采购经理指数为 52%，装备制造业和高技术制造业稳中向好发展，制造业产业结构持续优化。 北京经济技术开发区：推进数模混合、存算一体等芯片架构研发创新 延伸场景定义芯片、行 业专用芯片、使能软件等产业链条 北京经济技术开发区管理委员会印发《关于进一步加快建设全域人工智能之城的实施方案 （2026—2027年）》。其中提到，夯实智能原生基础能力。发挥集成电路制造能力优势，推 动"设计-制造-封测-算力"一体化协同发展，牵引算力基础设施与高性能智算产业持续迭代。推 进数模混合、存算一体等芯片架构研发创新，延伸场景定义芯片、行业专用芯片、使能软件等 产业链条。推动通用与垂类模型协同发展，加快认知 ...